Daily Stock Analysis, PRGO, Perrigo Company PLC, priceseries

Perrigo Company PLC. Daily Stock Analysis
Stock Information
Open
36.96
Close
36.12
High
37.14
Low
36.06
Previous Close
37.23
Daily Price Gain
-1.11
YTD High
41.79
YTD High Date
Jan 11, 2022
YTD Low
34.27
YTD Low Date
Feb 24, 2022
YTD Price Change
-2.88
YTD Gain
-7.38%
52 Week High
50.18
52 Week High Date
Sep 30, 2021
52 Week Low
34.27
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-4.43
52 Week Gain
-10.91%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 25. 2017
62.50
May 17. 2017
67.58
16 Trading Days
8.12%
Link
LONG
Jun 25. 2019
43.01
Jul 17. 2019
46.99
15 Trading Days
9.25%
Link
LONG
Sep 5. 2019
45.73
Sep 24. 2019
50.88
13 Trading Days
11.28%
Link
LONG
Dec 4. 2019
48.33
Dec 24. 2019
51.32
14 Trading Days
6.20%
Link
LONG
Sep 2. 2021
40.83
Sep 17. 2021
43.40
10 Trading Days
6.31%
Link
Company Information
Stock Symbol
PRGO
Exchange
NYSE
Company URL
http://www.perrigo.com
Company Phone
269-673-8451
CEO
John T. Hendrickson
Headquarters
-
Business Address
TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN, IRELAND L2 2
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Related Products
CIK
0001585364
About

Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences. The CHC segment includes the company's former segments, which are the Nutritionals and Israel Pharmaceuticals and Diagnostics business. The BCH segment consists of the Omega business. The Prescription Pharmaceuticals includes the Rx Pharmaceuticals business. The Specialty Sciences segment comprises of the assets, which focuses on the treatment of multiple sclerosis. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Description

Perrigo Company plc, together with its subsidiaries, develops, manufactures, markets, and distributes over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. The company operates through Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx), Specialty Sciences, and Other segments. The CHC segment offers OTC products in various categories, including analgesics, cough/cold/allergy/sinus, gastrointestinal, infant nutritional, smoking cessation, animal health, feminine hygiene, diabetes and dermatological care, diagnostic, scar management, and other healthcare products, as well as vitamins, minerals, and dietary supplements (VMS); and contract manufacturing services. It serves retail drug, supermarket, mass merchandise chains, and wholesalers through sales force and industry brokers. The BCH segment provides branded OTC products in the natural health and VMS; cough, cold, flu, and allergy; personal care and derma-therapeutics; lifestyle; pain relief, nasal decongestants, and cold sore management; and anti-parasite areas, as well as offers generic pharmaceutical products. It serves pharmacies, drug, and grocery stores through pharmacy sales force, as well as a network of pharmacists. The Rx segment offers generic and specialty pharmaceutical prescription drugs in various dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, women's health products, oral solid dosage forms, and oral liquid formulations; and ORx products. It serves wholesalers; retail drug, supermarket, and mass merchandise chains; hospitals; and pharmacies. The Specialty Sciences segment offers Tysabri to treat multiple sclerosis. The Other segment offers active pharmaceutical ingredients used by generic and branded pharmaceutical companies. The company was founded in 1887 and is headquartered in Dublin, Ireland.